{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:56:26Z","timestamp":1790902586114,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016304","name":"Medtronic Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hlc.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:50:16Z","timestamp":1785358216000},"page":"1487-1497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Radiofrequency Renal Denervation for Resistant Hypertension in Australia"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-0195","authenticated-orcid":false,"given":"Markus P.","family":"Schlaich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Ryschon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray D.","family":"Esler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6106-467X","authenticated-orcid":false,"given":"Alessandro","family":"Ciorra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan B.","family":"Pietzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2026.04.006_bib1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5694\/mja2.52373","article-title":"National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030","volume":"221","author":"Schutte","year":"2024","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2026.04.006_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/HJH.0000000000003854","article-title":"Prevalence, awareness, treatment, and control rtes of hypertension in the general population of Australia: a systematic review and meta-analysis","volume":"43","author":"Wang","year":"2025","journal-title":"J Hypertens"},{"key":"10.1016\/j.hlc.2026.04.006_bib3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2026.04.006_bib4","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/HJH.0000000000002933","article-title":"European Society of Hypertension position paper on renal denervation 2021","volume":"39","author":"Schmieder","year":"2021","journal-title":"J Hypertens"},{"key":"10.1016\/j.hlc.2026.04.006_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4244\/EIJ-D-19-00902","article-title":"Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation","volume":"16","author":"Townsend","year":"2020","journal-title":"EuroIntervention"},{"key":"10.1016\/j.hlc.2026.04.006_bib6","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"B\u00f6hm","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2026.04.006_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.jacc.2023.08.045","article-title":"Safety and efficacy of renal denervation in patients taking antihypertensive medications","volume":"82","author":"Kandzari","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2026.04.006_bib8","article-title":"Long-term outcomes following radiofrequency renal denervation: meta-analysis of 18 reports","author":"Mahfoud","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hlc.2026.04.006_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/ehjqcco\/qcac056","article-title":"Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry","volume":"9","author":"Schmieder","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.hlc.2026.04.006_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fphys.2012.00134","article-title":"Effects of renal sympathetic denervation on 24-hour blood pressure variability","volume":"3","author":"Zuern","year":"2012","journal-title":"Front Physiol"},{"key":"10.1016\/j.hlc.2026.04.006_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/HYPERTENSIONAHA.119.13081","article-title":"Changes in 24-hour patterns of blood pressure in hypertension following renal denervation therapy","volume":"74","author":"Kario","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.hlc.2026.04.006_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.125.015194","article-title":"Long-term safety and efficacy of renal denervation: 24-month results from the SPYRAL HTN-ON MED trial","volume":"18","author":"Kandzari","year":"2025","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.hlc.2026.04.006_bib13","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1161\/HYPERTENSIONAHA.123.22314","article-title":"Long-term blood pressure reductions following catheter-based renal denervation: a systematic review and meta-analysis","volume":"81","author":"Sesa-Ashton","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.hlc.2026.04.006_bib14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.124.069709","article-title":"Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis","volume":"150","author":"Vukadinovi\u0107","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2026.04.006_bib15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/HJH.0000000000003727","article-title":"Renal denervation for uncontrolled hypertension: a systematic review and meta-analysis examining multiple subgroups","volume":"42","author":"Sharp","year":"2024","journal-title":"J Hypertens"},{"key":"10.1016\/j.hlc.2026.04.006_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101606","article-title":"Long-Term, Patient-Level Analysis of Radiofrequency Renal Denervation in the SYMPLICITY Clinical Trial Program","volume":"4","author":"Mahfoud","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.hlc.2026.04.006_bib17","first-page":"e114","volume":"152","author":"Writing Committee Members\u2217","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2026.04.006_bib18","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1161\/HYP.0000000000000240","article-title":"Renal denervation for the treatment of hypertension: a scientific statement from the American Heart Association","volume":"81","author":"Cluett","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.hlc.2026.04.006_bib19","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2026.04.006_bib20","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.hlc.2026.04.006_bib21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ehjqcco\/qcae001","article-title":"Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence","volume":"10","author":"Sharp","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.hlc.2026.04.006_bib22","article-title":"Catheter-based radiofrequency renal denervation in the United States: A cost-effectiveness analysis based on contemporary evidence","volume":"3","author":"Kandzari","year":"2024","journal-title":"J Soc CardioVasc Angiogr Interv"},{"key":"10.1016\/j.hlc.2026.04.006_bib23","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/jch.14922","article-title":"Cost-effectiveness of radiofrequency renal denervation for uncontrolled hypertension in Japan","volume":"26","author":"Kario","year":"2024","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.hlc.2026.04.006_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/08037051.2025.2487583","article-title":"Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Sweden","volume":"34","author":"Kahan","year":"2025","journal-title":"Blood Press"},{"key":"10.1016\/j.hlc.2026.04.006_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/13696998.2024.2441072","article-title":"Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Canada","volume":"28","author":"McFarlane","year":"2025","journal-title":"J Med Econ"},{"key":"10.1016\/j.hlc.2026.04.006_bib26","first-page":"305","article-title":"Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain","volume":"6","author":"Rodr\u00edguez-Leor","year":"2024","journal-title":"REC Interv Cardiol"},{"key":"10.1016\/j.hlc.2026.04.006_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/jch.70090","article-title":"Cost-effectiveness of radiofrequency renal denervation in Taiwan based on clinical evidence and regional event rates","volume":"27","author":"Huang","year":"2025","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.hlc.2026.04.006_bib28","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jacc.2012.07.029","article-title":"Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension","volume":"60","author":"Geisler","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2026.04.006_bib29","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/ajh\/hpy108","article-title":"Cost-effectiveness of renal denervation therapy for treatment-resistant hypertension: a best case scenario","volume":"31","author":"Chowdhury","year":"2018","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.hlc.2026.04.006_bib30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0002-8703(00)90236-9","article-title":"Primary and subsequent coronary risk appraisal: new results from the Framingham study","volume":"139","author":"D'Agostino","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.hlc.2026.04.006_bib31","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/CIRCULATIONAHA.108.784215","article-title":"Long-term trends in the incidence of heart failure after myocardial infarction","volume":"118","author":"Velagaleti","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2026.04.006_bib32","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/ije\/31.6.1253","article-title":"Prediction of risk of coronary events in middle-aged men in the Prospective cardiovascular M\u00fcnster Study (PROCAM) using neural networks","volume":"31","author":"Voss","year":"2002","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.hlc.2026.04.006_bib33","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1161\/STROKEAHA.107.510362","article-title":"Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke","volume":"39","author":"Saposnik","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.hlc.2026.04.006_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jstrokecerebrovasdis.2005.06.002","article-title":"Sex differences in stroke survival: 10-year follow-up of the Copenhagen stroke study cohort","volume":"14","author":"Andersen","year":"2005","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.hlc.2026.04.006_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","article-title":"Probability of stroke: a risk profile from the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.hlc.2026.04.006_bib36","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.hlc.2026.04.006_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5694\/mja16.00525","article-title":"Risk-adjusted hospital mortality rates for stroke: evidence from the Australian Stroke Clinical Registry (AuSCR)","volume":"206","author":"Cadilhac","year":"2017","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2026.04.006_bib38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/1471-2458-12-281","article-title":"Mortality after admission for acute myocardial infarction in Aboriginal and non-Aboriginal people in New South Wales, Australia: a multilevel data linkage study","volume":"12","author":"Randall","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.hlc.2026.04.006_bib39","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/ejhf.2595","article-title":"Long-term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand","volume":"24","author":"Hariharaputhiran","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2026.04.006_bib40","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.111.964700","article-title":"Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010","volume":"5","author":"Smolina","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.hlc.2026.04.006_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b3058","article-title":"Five year prognosis in patients with angina identified in primary care: incident cohort study","volume":"339","author":"Buckley","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.hlc.2026.04.006_bib44","unstructured":"Medtronic. SPYRAL HTN-ON MED and Global SYMPLICITY Registry (GSR) DEFINE Data on File. [accessed 18.7.26]."},{"key":"10.1016\/j.hlc.2026.04.006_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5694\/mja16.00526","article-title":"Guideline for the diagnosis and management of hypertension in adults\u20142016","volume":"205","author":"Gabb","year":"2016","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2026.04.006_bib46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/emermed-2022-212674","article-title":"Healthcare cost burden of acute chest pain presentations","volume":"40","author":"Dawson","year":"2023","journal-title":"Emerg Med J"},{"key":"10.1016\/j.hlc.2026.04.006_bib47","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1071\/AH22180","article-title":"Costs of major complications in people with and without diabetes in Tasmania, Australia","volume":"46","author":"Dinh","year":"2022","journal-title":"Aust Health Rev"},{"key":"10.1016\/j.hlc.2026.04.006_bib48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5694\/mja2.52424","article-title":"Hospital costs for unplanned re-admissions within 30 days of hospitalisations with heart failure, Australia, 2013\u20132017: a retrospective cohort study","volume":"221","author":"Dang","year":"2024","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2026.04.006_bib49","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s41371-020-0363-z","article-title":"Health care utilisation and out-of-pocket expenditure associated with hypertension: an analysis of Australian adults from the 45 and Up Study","volume":"34","author":"Adams","year":"2020","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.hlc.2026.04.006_bib50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11606-025-09423-8","article-title":"Current and future cost burden of myocardial infarction in Australia: dynamic multistate markov model","volume":"41","author":"Abebe","year":"2025","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.hlc.2026.04.006_bib51","author":"Kim"},{"key":"10.1016\/j.hlc.2026.04.006_bib54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12955-016-0537-0","article-title":"Health-related quality of life measured using the EQ-5D\u20135L: South Australian population norms","volume":"14","author":"McCaffrey","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.hlc.2026.04.006_bib55","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024296","article-title":"Health state utility values in people with stroke: a systematic review and meta-analysis","volume":"11","author":"Joundi","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hlc.2026.04.006_bib56","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12955-020-01559-x","article-title":"Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review","volume":"18","author":"Cooper","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.hlc.2026.04.006_bib57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s41669-022-00364-0","article-title":"Cost effectiveness of ambulatory blood pressure monitoring compared with home or clinic blood pressure monitoring for diagnosing hypertension in Australia","volume":"7","author":"Shah","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.hlc.2026.04.006_bib58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12955-020-01407-y","article-title":"Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review","volume":"18","author":"Betts","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.hlc.2026.04.006_bib59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40273-020-00984-6","article-title":"Health state utilities of patients with heart failure: a systematic literature review","volume":"39","author":"Di Tanna","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.hlc.2026.04.006_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.hlc.2026.04.006_bib61","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3111\/13696998.2014.978453","article-title":"Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in the Netherlands","volume":"18","author":"Henry","year":"2015","journal-title":"J Med Econ"},{"key":"10.1016\/j.hlc.2026.04.006_bib63","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","article-title":"Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC-does the presence of an explicit threshold affect the ICER proposed?","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.hlc.2026.04.006_bib64","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.jacc.2020.04.036","article-title":"Renal denervation in high-risk patients with hypertension","volume":"75","author":"Mahfoud","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2026.04.006_bib65","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2026.04.006_bib66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","article-title":"The valsartan antihypertensive long-term use evaluation (VALUE) trial: outcomes in patients receiving monotherapy","volume":"48","author":"Julius","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.hlc.2026.04.006_bib67","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2026.04.006_bib68","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2026.04.006_bib69","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2026.04.006_bib70","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Ontarget Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2026.04.006_bib71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2026.04.006_bib72","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2026.04.006_bib73","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2026.04.006_bib75","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.122.008997","article-title":"Patient preferences for pharmaceutical and device-based treatments for uncontrolled hypertension: discrete choice experiment","volume":"16","author":"Kandzari","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.hlc.2026.04.006_bib76","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00392-019-01468-0","article-title":"Patient preference for therapies in hypertension: a cross-sectional survey of German patients","volume":"108","author":"Schmieder","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.hlc.2026.04.006_bib77","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2021.01.014","article-title":"Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension","volume":"77","author":"Fatani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2026.04.006_bib78","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2026.04.006_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.hlc.2026.04.006_bib80","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950626002507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950626002507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:48:36Z","timestamp":1790902116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950626002507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":74,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1443950626002507"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2026.04.006","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Radiofrequency Renal Denervation for Resistant Hypertension in Australia","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}